Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ArQule

Bayer symbol

FDA clears Bayer/ Algeta’s prostate cancer radiotherapy

Approval for Xofigo comes three months ahead of schedule

- PMLiVE

FDA expands use of Roche/ Astellas’ Tarceva in lung cancer patients

New indication approved alongside companion diagnostic to detect gene mutation

- PMLiVE

FDA to review Merck & Co’s allergy immunotherapy

Accepts application for oral tablet to protect against ragweed-based allergies

- PMLiVE

Endocyte appoints Parexel’s Scot Harper to oversee clinical trials

He also previously served at Novartis and Lilly

- PMLiVE

Merck & Co wins green light in US for Zetia-Lipitor combo

Vytorin extension wins FDA approval

- PMLiVE

Roche survey says Scottish cancer patients moving house to get treatment

But NHS Scotland hits back at report's "extremely dubious" findings

- PMLiVE

FDA committee turns down Aveo/Astellas’ cancer drug

Tivozanib unable to prove superiority to Bayer's Nexavar

- PMLiVE

FDA says Janssen’s myeloma drug is a ‘breakthrough therapy’

Should speed up regulatory process for daratumumab

- PMLiVE

Merck & Co enters $430m diabetes deal with Abide

Will target group of enzymes known as serine hydrolases

- PMLiVE

Merck & Co and Pfizer join forces on diabetes candidate

Latest big pharma alliance involving an SGLT2 inhibitor

- PMLiVE

Two new cancer drugs recommended in Europe

CHMP backing for Roche's Erivedge and Astellas' Xtandi

- PMLiVE

EC gives green light to new 6-in-1 childhood vaccine from Sanofi, MSD

Hexyon/Hexacima protects against diphtheria, DTP, hepatitis B, polio, meningitis and Haemophilus influenzae type B

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links